Fezolinetant: First FDA Approved Treatment for Moderate-to-Severe Vasomotor Symptoms Associated with Menopause

Posted on:May 19, 2023
Last Updated: November 30, 2023
Time to read: 4 minutes

The U.S. Food and Drug Administration approved Veozah (Fezolinetant), an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause.

Veozah is the first neurokinin 3 (NK3) receptor antagonist approved by the FDA to treat moderate to severe hot flashes (flushes)  from menopause.

Vasomotor symptoms, including hot flashes and night sweats, significantly impact the quality of life for many women experiencing menopause. Current treatment approaches primarily involve hormone replacement therapy (HRT), but alternative options are needed due to contraindications or individual preferences. Fezolinetant, a neurokinin 3 (NK3) receptor antagonist, presents a novel and promising avenue for addressing these symptoms.

Perimenopausal Depression – A Review of Diagnosis and Management

Tibolone As Adjunctive Treatment in Perimenopausal Depression By Prof Jayashri Kulkarni

HRT vs Antidepressants in Perimenopausal Depression By Prof Jayashri Kulkarni

References